LRRK2 Inhibitors

Mutations in the LRRK2 gene are risk-factors for developing Parkinson’s disease. Increased kinase activity of certain LRRK2 mutants is thought to underlie dopaminergic neuron damage. Thus, LRRK2 inhibitors offer the potential to target an underlying cause of the disease. Here is the latest research.

September 17, 2021
Preprint
Open Access

Small molecule screen employing patient-derived iPS hepatocytes identifies LRRK2 as a novel therapeutic target for Alpha1 Antitrypsin Deficiency

BioRxiv : the Preprint Server for Biology
D. KentS. Tamir Rashid
August 30, 2021

Effects of Telmisartan, an AT1 receptor antagonist, on mitochondria-specific genes expression in a mouse MPTP model of Parkinsonism.

Frontiers in Bioscience (Landmark Edition)
Bipul RaySaravana Babu Chidambaram
August 30, 2021
Preprint
Open Access

Nanobodies as allosteric modulators of Parkinson's disease-associated LRRK2

BioRxiv : the Preprint Server for Biology
R. K. SinghW. Versees
July 8, 2021
Open Access

Ciliogenesis is Not Directly Regulated by LRRK2 Kinase Activity in Neurons.

Experimental Neurobiology
Hyejung KimWongi Seol
June 25, 2021
Open Access

LRRK2-NFATc2 Pathway Associated with Neuroinflammation May Be a Potential Therapeutic Target for Parkinson's Disease.

Journal of Inflammation Research
Youcui WangJunxia Xie
June 19, 2021
Open Access

Protein phosphatase 2A holoenzymes regulate leucine-rich repeat kinase 2 phosphorylation and accumulation.

Neurobiology of Disease
Matthieu DrouyerJean-Marc Taymans
June 3, 2021
Open Access

BORCS6 is involved in the enlargement of lung lamellar bodies in Lrrk2 knockout mice.

Human Molecular Genetics
Miho ArakiTaisuke Tomita
April 25, 2021

A Disease Progression Model to Quantify the Nonmotor Symptoms of Parkinson's Disease in Participants With Leucine-Rich Repeat Kinase 2 Mutation.

Clinical Pharmacology and Therapeutics
Malidi AhamadiCritical Path for Parkinson’s Consortium
February 23, 2021
Preprint
Open Access

Understanding LRRK2 kinase activity in preclinical models and human subjects through quantitative analysis of LRRK2 and pRab10

BioRxiv : the Preprint Server for Biology
X. WangAnastasia G. Henry
February 19, 2021

Genetic background influences LRRK2-mediated Rab phosphorylation in the rat brain.

Brain Research
Kaela KellyAndrew B. West
February 3, 2021
Review

The Cell Biology of LRRK2 in Parkinson's Disease.

Molecular and Cellular Biology
Ahsan UsmaniAnnie Hiniker
December 17, 2020
Review
Open Access

NEAT1 on the Field of Parkinson's Disease: Offense, Defense, or a Player on the Bench?

Journal of Parkinson's Disease
Fanni Annamária BorosPéter Klivényi
November 17, 2020

Selective Inhibitors of G2019S-LRRK2 Kinase Activity.

Journal of Medicinal Chemistry
Albert W GarofaloHolly J Carlisle
November 17, 2020
Open Access

Simplified Brain Organoids for Rapid and Robust Modeling of Brain Disease

Frontiers in Cell and Developmental Biology
Jeongmin HaJanghwan Kim
November 3, 2020
Open Access

Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity.

The Biochemical Journal
Alexia F KalogeropulouDario R Alessi

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved
/feed-previews/lrrk2-inhibitors/283fc400-1ae4-4464-8bfe-28c5d4831403